Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]**

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Lab: NCTR

C Number: C20310C

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

Lock Date: 12/01/2008

Cage Range: ALL

Date Range: ALL

Reasons For Removal: ALL

Removal Date Range: ALL

Include ALL **Treatment Groups:**

Study Gender: Female

TDMSE Version: 2.1.0 Time Report Requested: 16:30:29

First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS) CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo I
isposition Summary						
Animals Initially in Study	27	26	26	27	27	27
Early Deaths Moribund Sacrifice	1		1			1
Natural Death	1			1	1	
Survivors						
Moribund Sacrifice	1		1	2	1	2
Natural Death	2.4		1	1	1	3
Terminal Sacrifice	24	26	23	23	24	21
Animals Examined Microscopically	27	26	26	27	27	27
LIMENTARY SYSTEM						
Esophagus	(23)	(25)	(26)	(27)	(27)	(27)
Adventitia, Foreign Body	1					
Adventitia, Necrosis	1 [2.0]			1 [2.0]		
Gallbladder	(24)	(25)	(25)	(26)	(27)	(25)
Intestine Large, Cecum	(26)	(26)	(25)	(27)	(25)	(24)
Hyperplasia, Lymphoid		2 [2.0]	2 [2.5]	2 [2.0]	3 [2.0]	2 [2.0]
Epithelium, Hyperplasia Intestine Large, Colon	(36)	(26)	(26)	(26)	1 [2.0] (27)	(25)
Intestine Large, Colon Intestine Large, Rectum	(26) (26)	(26) (26)	(26)	(26)	(27)	(25)
Hyperplasia, Lymphoid	(20)	(20)	(23)	1 [2.0]	1 [3.0]	(23)
Intestine Small, Ileum	(26)	(26)	(25)	(27)	(25)	(25)
Intestine Small, Jejunum	(26)	(26)	(25)	(27)	(25)	(25)
Liver	(26)	(26)	(26)	(27)	(27)	(27)
Basophilic Focus	(- /	(- /	(- /	(/	()	1 [2.0]
Hematopoietic Cell Proliferation					1 [1.0]	
Infiltration Cellular, Lymphocyte		1 [2.0]				1 [1.0]
Inflammation, Chronic Active	3 [1.0]	2 [1.0]		2 [1.0]	1 [1.0]	
Necrosis					1 [1.0]	
Tension Lipidosis	1 [1.0]	3 [2.0]	3 [1.0]	5 [1.6]	7 [1.1]	4 [1.0]
Vacuolization Cytoplasmic	1 [1.0]	1 [1.0]	6 [1.2]	4 [1.0]	3 [1.3]	10 [1.0]
Mesentery	(0)	(0)	(1)	(0)	(1)	(1)
Hemorrhage Fat, Necrosis			1 [3.0]		1 [3.0]	1 [3.0] 1 [4.0]
rai, เพียงใช้เอ					1 [3.0]	ı [4 .∪]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS) CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

Test Type: 26-39 WEEKS Route: GAVAGE

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Cytoplasmic Alteration Infiltration Cellular, Lymphocyte		1 [1.0]			1 [1.0]	1 [1.0] 3 [1.0]
Inflammation, Chronic Active		1 [1.0]			4.54.03	4 50 01
Acinar Cell, Degeneration Salivary Glands	(26)	(26)	(26)	(27)	1 [1.0] (26)	1 [2.0] (27)
Infiltration Cellular, Lymphocyte	14 [1.1]	7 [1.1]	15 [1.2]	14 [1.1]	10 [1.3]	10 [1.0]
Stomach, Forestomach	(26)	(26)	(26)	(27)	(27)	(27)
Stomach, Glandular	(26)	(26)	(25)	(27)	(25)	(25)
CARDIOVASCULAR SYSTEM						
Heart Bacterium	(26)	(26)	(26)	(27)	(27)	(26)
Cardiomyopathy	1 [1.0]			ı		
Congestion	1				2 [2.5]	
Inflammation, Chronic Active	4 [0.0]		1 [1.0]		1 [1.0]	1 [4.0]
Pericardium, Inflammation, Chronic Pericardium, Inflammation, Chronic	1 [3.0]	1 [2.0]				
Active		1 [2.0]				
Pericardium, Mineralization		1 [3.0]				
Pericardium, Necrosis				1 [2.0]		
ENDOCRINE SYSTEM						
Adrenal Cortex	(26)	(26)	(26)	(27)	(27)	(26)
Accessory Adrenal Cortical Nodule	1	1				
Vacuolization Cytoplasmic	2 [2.0]	0.4.[4.0]	05 [4 0]	05 [4 0]	07.[4.0]	0.4.[4.0]
Subcapsular, Hyperplasia Adrenal Medulla	23 [1.0] (26)	24 [1.0] (26)	25 [1.0] (25)	25 [1.2] (27)	27 [1.2] (27)	24 [1.2] (26)
Parathyroid Gland	(22)	(21)	(21)	(22)	(22)	(22)
Cyst	(22)	(21)	(21)	1 [1.0]	(22)	(22)
Infiltration Cellular, Lymphocyte	1 [1.0]			. [•]		
Pituitary Gland	(26)	(26)	(26)	(27)	(27)	(27)
Thyroid Gland	(26)	(25)	(25)	(27)	(27)	(26)
Cyst	1 [2.0]		4.54.01	1 [1.0]		
Degeneration			1 [1.0]	2 [1.0]		1
Ectopic Thymus Infiltration Cellular, Lymphocyte	1 [2.0]	1 [1.0]		2		1

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
GENERAL BODY SYSTEM						
Tissue NOS Abscess Mediastinum, Abscess Mediastinum, Foreign Body	(0)	(1) 1 [4.0]	(0)	(1)	(0)	(1) 1 [4.0] 1
GENITAL SYSTEM						
Clitoral Gland Degeneration	(24)	(25)	(25)	(26)	(26)	(27) 1 [3.0]
Ovary Cyst Pigmentation	(26)	(26) 1 [2.0]	(26)	(27) 1 [1.0]	(27) 1 [2.0]	(26) 1 [2.0] 1 [2.0]
Bilateral, Cyst Uterus Edema	(26)	(26)	(26)	(27)	1 [2.0] (27)	(27) 1 [3.0]
Infiltration Cellular, Polymorphonuclear Endometrium, Hyperplasia, Cystic Lumen, Dilatation Vagina	1 [2.0] 2 [1.5] (27)	1 [1.0] 2 [1.5] (26)	1 [2.0] 3 [1.3] 10 [1.2] (25)	3 [2.3] 4 [2.0] 12 [1.3] (27)	3 [2.0] 5 [2.0] 14 [1.6] (27)	3 [2.0] 5 [1.6] 8 [1.3] (24)
HEMATOPOIETIC SYSTEM						
Bone Marrow Myeloid Cell, Hyperplasia Lymph Node Lumbar, Hyperplasia, Lymphoid	(26) 3 [2.7] (3)	(26) 2 [3.0] (1)	(26) (1) 1 [2.0]	(26) (1)	(26) 4 [2.5] (0)	(26) 1 [2.0] (3) 1 [2.0]
Mediastinal, Hyperplasia, Lymphoid Mediastinal, Infiltration Cellular, Plasma Cell	2 [4.0] 1 [4.0]		. [2.0]			. [2.0]
Renal, Hyperplasia, Lymphoid Lymph Node, Mandibular Hyperplasia, Lymphoid Lymph Node, Mesenteric	(26) 3 [1.3] (24)	(25) 2 [1.5] (25)	(26) (26)	(27) (26)	(25) 2 [2.5] (26)	(26) (27)
Hyperplasia, Lymphoid Spleen Depletion Lymphoid	7 [1.6] (26) 1 [3.0]	11 [1.4] (26)	8 [1.4] (26)	6 [1.8] (26)	6 [1.3] (27)	6 [1.7] (27)
Hematopoietic Cell Proliferation	3 [3.7]	2 [3.5]	5 [2.8]	4 [2.0]	5 [3.0]	8 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Hyperplasia, Lymphoid Thymus Bacterium Cyst, Multiple	(26)	2 [3.5] (26)	4 [2.0] (24)	5 [2.2] (26) 1	7 [2.4] (23)	6 [1.8] (27)
Foreign Body Hyperplasia, Lymphoid Hyperplasia, Plasma Cell	3 [2.3] 1 [3.0]	2 [2.0]	3 [2.0]	1 2 [2.0]	3 [2.0]	2 [2.0]
Inflammation, Chronic Active Necrosis Adventitia, Inflammation, Chronic Epithelial Cell, Hyperplasia	1 [3.0] 1 [4.0] 1 [1.0]			1 [4.0]		1 [3.0]
INTEGUMENTARY SYSTEM						
Mammary Gland	(24)	(24)	(25)	(26)	(27)	(27)
Alveolus, Hyperplasia Skin	(26)	(26)	(26)	1 [2.0] (27)	(27)	(27)
MUSCULOSKELETAL SYSTEM						
Bone Bone, Femur Skeletal Muscle Atrophy Cyst	(0) (27) (27)	(0) (26) (26)	(0) (26) (26) 2 [2.0] 1 [4.0]	(1) (27) (27)	(0) (27) (27)	(1) (27) (27)
NERVOUS SYSTEM						
Brain, Brain Stem	(26)	(26)	(26)	(27)	(27)	(27)
Gliosis Brain, Cerebellum Brain, Cerebrum Compression	(26) (26)	(26) (26)	(26) (26)	1 [3.0] (27) (27)	(27) (27)	(27) (27) 1 [2.0]
Cyst Epithelial Inclusion Infiltration Cellular, Lymphocyte Mineralization Peripheral Nerve Axon, Degeneration	(0)	(0)	(2) 2 [2.5]	1 [1.0] 1 [1.0] (0)	4 [1.0] (0)	2 [1.0] (0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

Route: GAVAGE
Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Spinal Cord Axon, Degeneration	(0)	(0)	(1) 1 [2.0]	(0)	(0)	(0)
RESPIRATORY SYSTEM						
Lung Abscess	(26) 2 [4.0]	(26)	(26)	(27)	(26)	(27) 1 [4.0]
Bacterium	2 [4.0]			1		
Foreign Body Infiltration Cellular, Lymphocyte	1 [1.0]					1
Inflammation, Chronic Active Necrosis		1 [2.0]				1 [3.0] 1 [2.0]
Mediastinum, Foreign Body				1		1 [2.0]
Mediastinum, Inflammation, Chronic Active		1 [2.0]				
Mediastinum, Mineralization Mediastinum, Necrosis	1 [4.0]	1 [4.0]		1 [3.0]		
Nose	(26)	(26)	(26)	(27)	(27)	(27)
SPECIAL SENSES SYSTEM						
Eye	(26)	(26)	(25)	(25)	(26)	(24)
Cataract Harderian Gland	(26)	(26)	1 [1.0] (26)	(27)	(27)	(25)
Infiltration Cellular, Lymphocyte	1 [1.0]	,	,	,	,	,
URINARY SYSTEM						
Kidney	(26)	(26)	(26)	(27)	(27)	(27)
Casts Protein Cyst			1 [1.0] 1 [1.0]	1 [1.0]	3 [1.0]	2 [1.0] 1 [1.0]
Glomerulosclerosis Hydronephrosis			,		1 [4.0]	1 [3.0]
Infiltration Cellular, Lymphocyte	8 [1.1]	3 [1.0]	9 [1.1]	6 [1.2]	5 [1.0]	4 [1.0]
Inflammation, Suppurative Inflammation, Chronic Active	1 [1.0]				1 [4.0]	
Metaplasia, Osseous Mineralization	1		1 [1 0]	1 [1.0]		
wiirerdiiZation			1 [1.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29

Date Report Requested: 06/29/2009

First Dose M/F: NA / 11/18/04

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicle 6 mo F	AZT 120 6 mo F	Vehicle 9 mo F	AZT 40 9 mo F	AZT 80 9 mo F	AZT 120 9 mo F
Nephropathy Ureter Inflammation, Suppurative Lumen, Dilatation	(0)	(0)	(0)	(0)	1 [4.0] (1) 1 [3.0] 1 [2.0]	1 [3.0] (0)
Urinary Bladder Infiltration Cellular, Lymphocyte Lumen, Dilatation	(26) 3 [1.0]	(26) 1 [1.0]	(26) 1 [1.0]	(27) 4 [1.0]	(27) 2 [1.0]	(26) 1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Disposition Summary		
Animals Initially in Study Early Deaths Moribund Sacrifice Natural Death Survivors	26	26
Moribund Sacrifice		3
Natural Death	1	o .
Terminal Sacrifice	25	23
Animals Examined Microscopically	26	26
ALIMENTARY SYSTEM		
Esophagus Adventitia, Foreign Body Adventitia, Necrosis	(26)	(25)
Gallbladder	(25)	(26)
Intestine Large, Cecum	(25)	(26)
Hyperplasia, Lymphoid Epithelium, Hyperplasia	3 [2.0]	
Intestine Large, Colon	(25)	(26)
Intestine Large, Rectum Hyperplasia, Lymphoid	(25)	(26)
Intestine Small, Ileum	(25)	(26)
Intestine Small, Jejunum	(25)	(26)
Liver	(25)	(26)
Basophilic Focus		1
Hematopoietic Cell Proliferation Infiltration Cellular, Lymphocyte	2 [4 0]	1 [1 0]
Inflammation, Chronic Active	2 [1.0] 2 [1.0]	1 [1.0]
Necrosis	[۱.0]	
Tension Lipidosis	3 [1.3]	4 [1.5]
Vacuolization Cytoplasmic	12 [1.0]	6 [1.0]
Mesentery	(0)	(0)
Hemorrhage	(-)	\ - /
Fat, Necrosis		
Pancreas	(26)	(26)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Cytoplasmic Alteration Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Acinar Cell, Degeneration Salivary Glands Infiltration Cellular, Lymphocyte Stomach, Forestomach Stomach, Glandular	(25) 15 [1.1] (25) (25)	(26) 12 [1.2] (26) (26)
CARDIOVASCULAR SYSTEM		
Heart Bacterium Cardiomyopathy Congestion Inflammation, Chronic Active Pericardium, Inflammation, Chronic Pericardium, Inflammation, Chronic Active Pericardium, Mineralization Pericardium, Necrosis	(25)	(26)
ENDOCRINE SYSTEM		
Adrenal Cortex Accessory Adrenal Cortical Nodule Vacuolization Cytoplasmic	(26)	(26)
Subcapsular, Hyperplasia Adrenal Medulla Parathyroid Gland Cyst	23 [1.2] (26) (25)	24 [1.1] (26) (24)
Infiltration Cellular, Lymphocyte Pituitary Gland Thyroid Gland Cyst	(26) (26)	(26) (26)
Degeneration Ectopic Thymus Infiltration Cellular, Lymphocyte	2	1 [1.0] 1

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

CODEEA - Francischer Alberta MOTO MOTO	Valial PND4 0 F	A 7T 40 DND4 0 T
C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
GENERAL BODY SYSTEM		
Tissue NOS Abscess Mediastinum, Abscess Mediastinum, Foreign Body	(0)	(0)
GENITAL SYSTEM		
Clitoral Gland Degeneration	(26)	(25)
Ovary Cyst	(26) 4 [2.3]	(26) 1 [2.0]
Pigmentation Bilateral, Cyst		
Uterus Edema	(26)	(26)
Infiltration Cellular, Polymorphonuclear Endometrium, Hyperplasia, Cystic	1 [2.0] 4 [1.5]	3 [1.7]
Lumen, Dilatation Vagina	16 [1.5] (26)	13 [1.2] (25)
HEMATOPOIETIC SYSTEM		
Bone Marrow Myeloid Cell, Hyperplasia	(25)	(26)
Lymph Node Lumbar, Hyperplasia, Lymphoid	(0)	(2)
Mediastinal, Hyperplasia, Lymphoid Mediastinal, Infiltration Cellular, Plasma Cell		
Renal, Hyperplasia, Lymphoid Lymph Node, Mandibular	(25)	1 [1.0] (25)
Hyperplasia, Lymphoid Lymph Node, Mesenteric	(25)	1 [1.0] (26)
Hyperplasia, Lymphoid Spleen	4 [1.5] (26)	3 [1.0] (26)
Depletion Lymphoid Hematopoietic Cell Proliferation	2 [3.0]	2 [2.0]
,		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Hyperplasia, Lymphoid Thymus Bacterium	6 [2.3] (25)	6 [2.2] (25)
Cyst, Multiple Foreign Body		1 [4.0]
Hyperplasia, Lymphoid Hyperplasia, Plasma Cell Inflammation, Chronic Active Necrosis Adventitia, Inflammation, Chronic Epithelial Cell, Hyperplasia	1 [2.0]	3 [1.3]
INTEGUMENTARY SYSTEM		
Mammary Gland Alveolus, Hyperplasia	(26)	(26)
Skin	(26)	(26)
MUSCULOSKELETAL SYSTEM		
Bone Bone, Femur Skeletal Muscle Atrophy Cyst	(0) (26) (26)	(0) (26) (26)
NERVOUS SYSTEM		
Brain, Brain Stem Gliosis	(26)	(26)
Brain, Cerebellum Brain, Cerebrum Compression Cyst Epithelial Inclusion	(26) (26)	(26) (26)
Infiltration Cellular, Lymphocyte Mineralization Peripheral Nerve Axon, Degeneration	2 [1.0] (0)	4 [1.0] (0)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS) CAS Number: 30516-87-1

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Spinal Cord Axon, Degeneration	(0)	(0)
RESPIRATORY SYSTEM		
Lung Abscess Bacterium Foreign Body	(26)	(26)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active		1 [2.0] 1 [1.0]
Necrosis Mediastinum, Foreign Body Mediastinum, Inflammation, Chronic Active		
Mediastinum, Mineralization Mediastinum, Necrosis Nose	(26)	(26)
SPECIAL SENSES SYSTEM		
Eye Cataract	(25)	(26)
Harderian Gland Infiltration Cellular, Lymphocyte	(25)	(26)
URINARY SYSTEM		
Kidney Casts Protein Cyst Glomerulosclerosis	(25)	(26)
Hydronephrosis Infiltration Cellular, Lymphocyte Inflammation, Suppurative Inflammation, Chronic Active Metaplasia, Osseous Mineralization	9 [1.1]	5 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Route: GAVAGE

Test Type: 26-39 WEEKS

Species/Strain: MICE/C3B6F1-+/Trp53(tm1Brd)

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]

3'-Azido-3'-deoxythymidine (AIDS)

CAS Number: 30516-87-1

Time Benert Beguested: 16:20:20

Time Report Requested: 16:30:29 First Dose M/F: NA / 11/18/04

Date Report Requested: 06/29/2009

Lab: NCTR

C3B6F1-+/Trp53(tm1Brd) NCTR MICE FEMALE	Vehicl PND1-8 F	AZT 40 PND1-8 F
Nephropathy Ureter	(0)	(0)
Inflammation, Suppurative Lumen, Dilatation	(0)	(0)
Urinary Bladder	(25)	(26)
Infiltration Cellular, Lymphocyte Lumen, Dilatation	2 [1.0] 1 [4.0]	3 [1.0]

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)